442 related articles for article (PubMed ID: 32413051)
21. Plasmatic dermatan sulfate and chondroitin sulfate determination in mucopolysaccharidoses.
Volpi N; Maccari F; Galeotti F; Zampini L; Santoro L; Padella L; Galeazzi T; Gabrielli O; Coppa GV
J Pharm Biomed Anal; 2013 Nov; 85():40-5. PubMed ID: 23872470
[TBL] [Abstract][Full Text] [Related]
22. Mucopolysaccharidosis VI.
Valayannopoulos V; Nicely H; Harmatz P; Turbeville S
Orphanet J Rare Dis; 2010 Apr; 5():5. PubMed ID: 20385007
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI.
Bartolomeo R; Polishchuk EV; Volpi N; Polishchuk RS; Auricchio A
J Inherit Metab Dis; 2013 Mar; 36(2):363-71. PubMed ID: 22971959
[TBL] [Abstract][Full Text] [Related]
24. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.
Byers S; Rozaklis T; Brumfield LK; Ranieri E; Hopwood JJ
Mol Genet Metab; 1998 Dec; 65(4):282-90. PubMed ID: 9889015
[TBL] [Abstract][Full Text] [Related]
25. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
[TBL] [Abstract][Full Text] [Related]
26. Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.
D'Avanzo F; Zanetti A; De Filippis C; Tomanin R
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948256
[TBL] [Abstract][Full Text] [Related]
27. Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal development.
Hwang-Wong E; Amar G; Das N; Zhang X; Aaron N; Gale K; Rothman N; Fante M; Baik A; Bhargava A; Fricker A; McAlister M; Rabinowitz J; Lees-Shepard J; Nannuru K; Economides AN; Cygnar KD
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37751300
[TBL] [Abstract][Full Text] [Related]
28. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin.
Myers AL; Upreti VV; Khurana M; Eddington ND
J Clin Pharmacol; 2008 Oct; 48(10):1158-70. PubMed ID: 18757783
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.
Toomey JR; Abboud MA; Valocik RE; Koster PF; Burns-Kurtis CL; Pillarisetti K; Danoff TM; Erhardt JA
J Thromb Haemost; 2006 Sep; 4(9):1989-96. PubMed ID: 16961606
[TBL] [Abstract][Full Text] [Related]
31. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
32. Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients.
Lin WD; Lin SP; Wang CH; Hwu WL; Chuang CK; Lin SJ; Tsai Y; Chen CP; Tsai FJ
Clin Chim Acta; 2008 Aug; 394(1-2):89-93. PubMed ID: 18486607
[TBL] [Abstract][Full Text] [Related]
33. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
[TBL] [Abstract][Full Text] [Related]
34. Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.
Alliston T
J Pediatr Rehabil Med; 2010; 3(2):129-38. PubMed ID: 20628554
[TBL] [Abstract][Full Text] [Related]
35. Rhodamine B and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose (F-GlcNAc) inhibit chondroitin/dermatan and keratan sulphate synthesis by different mechanisms in bovine chondrocytes.
Derrick-Roberts AL; Marais W; Byers S
Mol Genet Metab; 2012 Jun; 106(2):214-20. PubMed ID: 22546219
[TBL] [Abstract][Full Text] [Related]
36. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
37. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.
Brands MM; Hoogeveen-Westerveld M; Kroos MA; Nobel W; Ruijter GJ; Özkan L; Plug I; Grinberg D; Vilageliu L; Halley DJ; van der Ploeg AT; Reuser AJ
Orphanet J Rare Dis; 2013 Apr; 8():51. PubMed ID: 23557332
[TBL] [Abstract][Full Text] [Related]
38. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
[TBL] [Abstract][Full Text] [Related]
39. Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases.
Tobacman JK; Bhattacharyya S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361933
[TBL] [Abstract][Full Text] [Related]
40. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.
Fillat C; Simonaro CM; Yeyati PL; Abkowitz JL; Haskins ME; Schuchman EH
J Clin Invest; 1996 Jul; 98(2):497-502. PubMed ID: 8755662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
